Halagon

RSS

halofuginone

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Halagon. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Halagon.

For practical information about using Halagon, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 26/02/2018

Authorisation details

Product details
Name
Halagon
Agency product number
EMEA/V/C/004201
Active substance
halofuginone lactate
International non-proprietary name (INN) or common name
halofuginone
Species
Calves, newborn
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP51AX08
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Emdoka BVBA
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
13/12/2016
Contact address
John Lijsenstraat 16
2321 Hoogstraten
Belgium

Product information

08/02/2018 Halagon - EMEA/V/C/004201 - IAIN/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Antiparasitic products
  • insecticides and repellents
  • Other antiprotozoal agents

Therapeutic indication

In newborn calves: • Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age. • Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.

Assessment history

How useful was this page?

Add your rating